Home/Investors/Mutual funds

Mutual funds

Biotech Investor · 2 portfolio companies

Portfolio

2

Combined Value

$396.4B

Focus Areas

15

Top Stage

Commercial

Investment Focus

Anti-malarials Pain Management (NSAIDs)Cardiovascular Anti-diabetics Anti-infectives Gastrointestinal CNS Dermatology Oncology Central Nervous System Immunology Gene Therapy Cell Therapy Infectious Disease Metabolic Disorders

Portfolio Companies

Company	Stage	Valuation	Focus
Ipca Laboratories	Commercial	$388.8B	Anti-malarials, Pain Management (NSAIDs)
Charles River Laboratories	Commercial	$7.6B	Oncology, Central Nervous System

Frequent Co-Investors

Public shareholders2 shared Institutional investors1 shared Promoter Group (Godha & Jain families)1 shared Foreign Institutional Investors (FIIs)1 shared